sectors sensex pharmaceutical sell stock nearly details know heres vaccines vials tata vaishali share close report snap remdesivir import children approved market companies pharma medical losing used shortage baricitinib losers

Articles for Cipla, search results for growth

Top stocks to watch today: Varun Beverages, Hero MotoCorp, Cipla, Grasim
Trending News
1 month, 1 week ago

Top stocks to watch today: Varun Beverages, Hero MotoCorp, Cipla, Grasim

India Today  

The stock markets are facing a tough week as Sensex and Nifty dropped close to 1.5% on Wednesday. The company reported an 8% growth in its standalone net profit for the quarter ending September 2024, reaching Rs 1,010 crore. TATA POWER Tata Power’s stock may see activity after the company announced the commissioning of a 126 MW floating solar project …

Market Company Stock Crore Quarter Net Vodafone
Home remedy: Indian pharma bets on domestic brands to combat US generics slowdown
1 month, 2 weeks ago

Home remedy: Indian pharma bets on domestic brands to combat US generics slowdown

Live Mint  

Indian pharma companies have long been key providers of generic medicines to the US market, accounting for 47% of all generic prescriptions in 2022, according to a recent report by the IQVIA Institute. Branded for growth Mankind Pharma Ltd, which earns 91% of its revenue from its domestic business and has a prescriber penetration rate of almost 84% as of …

Business India Indian Companies Sales Pharma Reddy
Sun Pharma: Down but not out?
1 month, 2 weeks ago

Sun Pharma: Down but not out?

Live Mint  

Sun Pharmaceutical Industries Ltd, India’s largest drugmaker, has long been a favourite among investors. And while the current financial year earnings estimates have not materially changed for Sun Pharma, the above development if not resolved quickly could lead to a 3% hit in its earnings for FY 26. Sun Pharma had reported a consolidated revenue from operations of ₹25,944 crore …

Market Pharma Crore Cipla Sun Pharma Generic Consolidated
Cipla share price: HSBC expects 13% upside for the stock post Q1 results on firm US prospects.
4 months, 3 weeks ago

Cipla share price: HSBC expects 13% upside for the stock post Q1 results on firm US prospects.

Live Mint  

Stock Market today: Cipla share price that has gained more than 24% year to date is trading near 52 week highs it scaled on Friday. Cipla had reported strong Q1 performance with net profit rising 17% YoY largely helped by improved operating performance as reported Ebitda grew 14% though revenue grew t a slower pace of 7% year-on-year. The same …

India Sales Hsbc Cipla Share Price Cipla Business Us Sales
Cipla net soars 43% on growth in India, other key markets
1 year, 1 month ago

Cipla net soars 43% on growth in India, other key markets

Live Mint  

Cipla Ltd posted a 43.4% rise in consolidated net profit for the quarter ended September to ₹1,130.91 crore, against ₹788.90 crore in the corresponding quarter of last year. The drug major’s Q2FY24 revenue increased 14.6% from a year ago from ₹5,828.54 crore to ₹6,678.15 crore, driven by performance in India, the US, and South Africa, it said in an exchange …

Business India South Africa Company Crore Quarter Key
Cipla among top pharma picks for Motilal Oswal as US sales to help boost growth
1 year, 3 months ago

Cipla among top pharma picks for Motilal Oswal as US sales to help boost growth

Live Mint  

In its research on the healthcare industry, brokerage firm Motilal Oswal Financial Services questions whether US generics will reverse the tide for the pharmaceutical companies given that the market's prospects have recently improved. "Sun Pharmaceutical Industries Ltd, Dr Reddy's Laboratories Ltd, Alkem Laboratories Ltd, and Ajanta Pharma Ltd have reduced filings in the US generics space over the past two …

Pharma Buy Cipla Filings Brokerage Motilal Oswal Dr Reddy
Cipla Shares Rally 9% After Q1 Results; Should You Buy, Sell or Hold The Pharma Stock?
1 year, 4 months ago

Cipla Shares Rally 9% After Q1 Results; Should You Buy, Sell or Hold The Pharma Stock?

News 18  

Cipla shares climbed 9 per cent in Thursday’s trade on Thursday after the pharma company reported robust earnings for the first quarter of FY24. Choice Broking said Cipla’s growth story for FY24-25 is premised on scaling up of its US formulations business across a complex portfolio and continued contribution from respiratory and peptide products on the back of new product …

Growth Cent Margin Key Eps Cipla Cipla Shares
Strong US sales growth, sustained domestic momentum helps Cipla beat estimates
1 year, 4 months ago

Strong US sales growth, sustained domestic momentum helps Cipla beat estimates

Live Mint  

Cipla's performance in the April-June quarter came better than expectations largely due to strong US sales performance. The analysts feel that contributions from multiple myeloma treatment drug Revlimid generics also contributed to the US sales growth. South Africa Private Market business grew at 13% YoY in local currency terms backed by double digit growth in both prescription and OTC business, …

Business India Market South Africa Launch Crore Yoy
Cipla Q1 net profit rises 45% to ₹996 crore; revenue growth at 18% YoY
1 year, 4 months ago

Cipla Q1 net profit rises 45% to ₹996 crore; revenue growth at 18% YoY

Live Mint  

Cipla reported a 45.1% rise in its consolidated net profit for the quarter ended June 2023 at ₹995.7 crore as compared to ₹696.4 crore in the corresponding quarter of the last year. The company’s US business reported the highest ever revenue of $ 222 million, registering a growth of 43% YoY growth driven by robust momentum in differentiated portfolios. South …

Business Growth Crore Yoy Cipla Profit Rises
Dr. Reddy’s becomes India’s second biggest drugmaker; details here
2 years, 1 month ago

Dr. Reddy’s becomes India’s second biggest drugmaker; details here

Firstpost  

Dr. Reddy’s Laboratories Ltd and Cipla Ltd have beaten Aurobindo Pharma to become India’s second and third biggest drugmakers, respectively, in terms of sales, in the quarter ended 30 September. Dr. Reddy’s and Cipla displaced Lupin later on, and it is the fifth largest company by sales now. Dr. Reddy’s earned Rs 6,331.8 crore as revenue in the September quarter, …

India Sales Reddy Cipla Dr Reddy Biggest Drug
Stocks to Watch: Maruti Suzuki, Cipla, Jubilant Foodworks, Yes Bank, Power Grid
4 years ago

Stocks to Watch: Maruti Suzuki, Cipla, Jubilant Foodworks, Yes Bank, Power Grid

Live Mint  

Here’s a list of top ten stocks that may be in news on Monday: Banks: Eight of India’s biggest lenders have seen a significant jump in wilful defaults in the six months to September, with such loans rising by over ₹37,000 crore to ₹1.5 trillion. Maruti Suzuki India: The country's largest carmaker looks to enter the diesel segment once again …

India Bank Jubilant Foodworks